Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New immune cell therapy takes on virus after transplant

NCT ID NCT07368634

Disease control Sponsor: Daihong Liu Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests a new treatment for Epstein-Barr virus (EBV) that can occur after a stem cell transplant. The treatment uses specially engineered immune cells (EBV-TCR-T cells) to find and destroy virus-infected cells. Up to 18 adult patients who have persistent EBV despite standard care will receive up to three infusions. The main goal is to check safety, but researchers will also see if the virus clears from the blood.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EBV-TCR-T cells (engineered immune cells designed to target and kill Epstein-Barr virus-infected cells)
What this could lead to
If successful, this could offer a new treatment option for controlling Epstein-Barr virus after stem cell transplants, potentially preventing serious complications like lymphoproliferative disorders.
What could go wrong
This is a very early, small trial (18 participants) testing safety first. The treatment may not work, and there are risks like cytokine release syndrome or other infusion reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 18 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years at the time of enrollment. * History of allogeneic hematopoietic stem cell transplantation. * Presence of Epstein-Barr virus (EBV) DNAemia confirmed by quantitative polymerase chain reaction (qPCR) in peripheral blood. * EBV DNAemia persisting or increasing despite standard management, as determined by the investigator. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. * Adequate organ function as defined by the study protocol. * Ability to understand and willingness to sign written informed consent. Exclusion Criteria: * Diagnosis of EBV-associated lymphoproliferative disorder requiring immediate cytotoxic chemotherapy. * Active, uncontrolled infection other than EBV. * History of severe autoimmune disease requiring systemic immunosuppressive therapy. * Uncontrolled graft-versus-host disease requiring high-dose systemic corticosteroids or other immunosuppressive treatment. * Prior treatment with EBV-specific adoptive T cell therapy within a defined washout period. * Known active malignancy other than EBV-related disease that may interfere with study participation. * Pregnant or breastfeeding women. * Any medical, psychological, or social condition that, in the opinion of the investigator, would interfere with safe participation in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epstein-Barr virus infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Epstein-Barr virus infection post-transplant lymphoproliferative disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epstein-Barr virus infection Post-transplant lymphoproliferative disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chinese PLA General Hospital

    RECRUITING

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.